Microcore has more than two decades of experiences in research, manufacturing and scale up of many Nutra-bioceuticals and Theraputicals.  Lactobacillus sporogenes is the previous name for Bacillus coagulans, a spore forming lactic acid producing probiotic. It behaves like Lactobacillus in the gut but has the stability of Bacillus due to its spore shell. Lactobacillus sporogenes, now correctly classified as Bacillus coagulans, is a unique, spore forming, lactic acid producing probiotic widely recognized for its stability, safety, and effectiveness. Although taxonomically a Bacillus species, it exhibits functional characteristics similar to Lactobacillus, making it an important organism in digestive and immune health applications. Unlike traditional Lactobacillus strains that are sensitive to heat, moisture, and stomach acidity, Bacillus coagulans forms resilient spores that protect the organism during processing, storage, and gastrointestinal transit. This spore-coating ensures exceptional stability and survivability, allowing it to reach the intestine alive, where it germinates, produces L-lactic acid, and helps restore a healthy balance of intestinal microflora. With a strong safety profile, GRAS status, and multiple clinical studies supporting its digestive, immune, and anti-inflammatory benefits, Bacillus coagulans is one of the most robust and reliable probiotics used in modern nutraceuticals, pharmaceuticals, and functional foods. Its ability to thrive in harsh conditions and deliver targeted gastrointestinal support makes it a preferred choice in adult, pediatric, and elderly formulations.

Significances

Lactobacillus sporogenes (Bacillus coagulans) is highly significant in modern probiotics due to its exceptional stability, proven clinical effectiveness, and wide applicability across health sectors. Its spore-forming nature allows it to withstand heat, acidity, and mechanical stress, enabling survival during manufacturing, storage, transport, and passage through the gastrointestinal tract. This resilience makes it ideal for incorporation into tablets, capsules, sachets, gummies, functional foods, and fortified nutritional products. Once the spores safely transit through the stomach, they germinate in the intestine, ensuring superior gut survival, high viability, and consistent therapeutic outcomes. Clinically, Bacillus coagulans demonstrates benefits in managing digestive disorders such as diarrhea, constipation, IBS, and bloating, while also enhancing gut immunity through increased secretory IgA production and reducing inflammatory markers to strengthen intestinal barrier function. Upon germination, it produces L-lactic acid, which helps maintain a healthy gut pH and inhibits pathogenic microorganisms. Recognized as safe (GRAS), it is suitable for adults, children, and the elderly, and widely used in pediatric products for diarrhea and general digestive support. Its broad utility extends to nutraceuticals, pharmaceuticals, dairy products, pediatric drops, and synbiotic formulations, with excellent compatibility alongside prebiotics and other probiotic strains. As a non-colonizing, transient probiotic, it exerts beneficial effects during passage through the gut without permanently altering the microbiota, ensuring a high safety profile and predictable performance.

• Where MRL 1025 Lactobacillus sporogenes (Bacillus coagulans) is used ?

  

  Lactobacillus sporogenes (Bacillus coagulans) is utilized extensively in clinical and nutritional applications due to its ability to survive gastric acidity and germinate in the intestinal environment, where it exerts multiple therapeutic effects. It is employed in the management of gastrointestinal disorders, including antibiotic-associated diarrhea, acute infectious diarrhea, irritable bowel syndrome (IBS), and inflammatory bowel diseases (IBD), owing to its capacity to modulate intestinal microbiota, enhance mucosal barrier integrity, and suppress pathogenic organisms through lactic acid and bacteriocin production. Additionally, B. coagulans has been shown to influence host immunity by increasing secretory IgA levels and regulating pro-inflammatory cytokines, thereby supporting both local and systemic immune responses. It is also incorporated into pediatric formulations to alleviate digestive disturbances such as colic, constipation, and rotavirus associated diarrhea due to its established safety profile. Furthermore, its high stability and spore-forming nature make it suitable for inclusion in a variety of nutraceutical preparations, functional foods, and synbiotic formulations aimed at promoting gastrointestinal health and reducing inflammatory burden.

• What are the advantages of Specific MRL 1025 Lactobacillus sporogenes (Bacillus coagulans) ?

   

  MRL 1025, a clinically utilized strain of Lactobacillus sporogenes (now classified as Bacillus coagulans), offers several distinct advantages due to its spore-forming capability, stability, and proven gastrointestinal benefits. Its spores demonstrate exceptional resistance to heat, moisture, and acidic environments, ensuring superior survival during processing, storage, and passage through the stomach. This high resilience results in excellent viability and consistent colon delivery, even at relatively low CFU doses. Once germinated in the intestine, MRL 1025 produces L lactic acid and antimicrobial compounds that help suppress pathogenic microorganisms, promote a healthy microbial balance, and support digestive function. Its ability to modulate inflammatory responses, strengthen intestinal barrier integrity, and enhance mucosal immunity (including increased secretory IgA) further contributes to its therapeutic value. Clinically, the strain is well tolerated across age groups including children making it suitable for managing diarrhea, IBS symptoms, dysbiosis, and inflammation-associated gastrointestinal disorders. Additionally, its stability without refrigeration and compatibility with a wide range of formulations (capsules, tablets, sachets, synbiotics, and functional foods) make MRL 1025 highly advantageous for nutraceutical and pharmaceutical applications.

  .

• How  the  MRL 1025 Lactobacillus sporogenes (Bacillus coagulans) Mechanism of action ?

  

   

  MRL 1025 exerts its probiotic effects through multiple complementary mechanisms. As a spore-forming organism, it survives gastric acidity and reaches the intestine intact, where its spores germinate into metabolically active vegetative cells. These cells produce L-lactic acid, which lowers intestinal pH and inhibits the growth of pathogenic bacteria. Additionally, MRL 1025 synthesizes bacteriocins and antimicrobial peptides that directly suppress harmful microorganisms, contributing to the restoration of microbial balance. The strain enhances intestinal barrier integrity by upregulating tight-junction proteins and reducing epithelial permeability, thereby protecting against mucosal damage. It also modulates immune responses, increasing levels of secretory IgA and regulating pro-inflammatory cytokines, leading to reduced gut inflammation. Furthermore, the strain improves digestive function by enhancing enzymatic activity and supporting beneficial commensal flora, creating a more resilient gastrointestinal environment. Collectively, these actions help maintain gut homeostasis, reduce pathogen burden, and support both local and systemic immune health.

   

• When the  MRL 1025 Lactobacillus sporogenes (Bacillus coagulans) will be launched by Microcore ?

  

  
  The developments are at lab scale and expected to complete clinical studies and further launch  by 2028

  
   

•